reasons why no targeted drug in nephrology treatment

Heterogeneity of kidney diseases: Kidney diseases are a diverse group of disorders that affect different parts of the kidney, with a wide range of underlying causes and disease mechanisms. This complexity makes it challenging to develop a targeted drug that can effectively treat all forms of kidney disease.

Limited understanding of disease mechanisms: Despite significant advances in the understanding of kidney biology and pathophysiology, the underlying mechanisms of many kidney diseases are still poorly understood. This makes it difficult to identify specific molecular targets for drug development.

Lack of reliable biomarkers: Biomarkers are critical tools for identifying patients who are most likely to benefit from a specific therapy. However, there are currently no reliable biomarkers for many kidney diseases, making it challenging to identify and select appropriate patient populations for clinical trials.

High risk of adverse effects: The kidneys play a critical role in drug metabolism and excretion, and many drugs can cause nephrotoxicity, leading to acute or chronic kidney injury. Therefore, there is a high risk of adverse effects associated with drugs that target the kidneys directly.

Limited investment in drug development: Kidney diseases have historically received less attention and funding than other disease areas, such as cancer and cardiovascular disease. This has resulted in limited investment in drug development and a lack of innovative therapies for kidney diseases.